4basebio (XTER:88Q) Equity-to-Asset : 0.30 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is 4basebio Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. 4basebio's Total Stockholders Equity for the quarter that ended in Jun. 2023 was €3.98 Mil. 4basebio's Total Assets for the quarter that ended in Jun. 2023 was €13.47 Mil. Therefore, 4basebio's Equity to Asset Ratio for the quarter that ended in Jun. 2023 was 0.30.

The historical rank and industry rank for 4basebio's Equity-to-Asset or its related term are showing as below:

XTER:88Q' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.64 Med: 0.77 Max: 0.88
Current: 0.3

During the past 4 years, the highest Equity to Asset Ratio of 4basebio was 0.88. The lowest was -1.64. And the median was 0.77.

XTER:88Q's Equity-to-Asset is ranked worse than
76.1% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs XTER:88Q: 0.30

4basebio Equity-to-Asset Historical Data

The historical data trend for 4basebio's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4basebio Equity-to-Asset Chart

4basebio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Equity-to-Asset

-1.64

0.87

0.80

0.61

4basebio Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Equity-to-Asset	Get a 7-Day Free Trial			0.88	0.80	0.77	0.61	0.30

Competitive Comparison of 4basebio's Equity-to-Asset

For the Biotechnology subindustry, 4basebio's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

4basebio's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4basebio's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where 4basebio's Equity-to-Asset falls into.

4basebio Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

4basebio's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )	=	Total Stockholders Equity	/	Total Assets
	=	8.187	/	13.44
	=	0.61

4basebio's Equity to Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

Equity to Asset (Q: Jun. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	3.975	/	13.467
	=	0.30

4basebio (XTER:88Q) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

4basebio Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of 4basebio's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

4basebio (XTER:88Q) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4basebio PLC (XTER:88Q) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

4BB:UK

Address

25 Norman Way, Over, Cambridge, GBR, CB24 5QE

Website

https://www.4basebio.com

4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for the effective and safe delivery of these DNA-based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high-purity, synthetic DNA for research, therapeutic and pharmacological use.

4basebio (XTER:88Q) Headlines

No Headlines